Argenica Therapeutics Limited (ASX:AGN)

Australia flag Australia · Delayed Price · Currency is AUD
0.6900
-0.0200 (-2.82%)
Jul 8, 2025, 12:28 PM AEST
-18.34%
Market Cap 88.63M
Revenue (ttm) 3.08M
Net Income (ttm) -5.26M
Shares Out 128.45M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 55,625
Average Volume 111,989
Open 0.7100
Previous Close 0.7100
Day's Range 0.6900 - 0.7100
52-Week Range 0.5950 - 0.9850
Beta 0.76
RSI 39.65
Earnings Date Aug 22, 2025

About Argenica Therapeutics

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol AGN
Full Company Profile

Financial Performance

In 2024, Argenica Therapeutics's revenue was 2.60 million, an increase of 48.46% compared to the previous year's 1.75 million. Losses were -5.48 million, 13.8% more than in 2023.

Financial Statements

News

There is no news available yet.